• OPEN AN ACCOUNT
Indian Indices
Nifty
24,715.05 135.45
(0.55%)
Sensex
80,567.71 409.83
( 0.51%)
Bank Nifty
54,067.55 406.55
( 0.76%)
Nifty IT
35,474.95 -262.95
( -0.74%)
Global Indices
Nasdaq
45,311.05 -254.84
(-0.56%)
Dow Jones
6,435.95 -45.31
(-0.70%)
Hang Seng
41,915.78 -394.71
(-0.93%)
Nikkei 225
9,116.69 -79.65
(-0.87%)
Forex
USD-INR
88.11 -0.04
(-0.04%)
EUR-INR
103.18 0.18
(0.18%)
GBP-INR
119.23 0.25
(0.21%)
JPY-INR
0.60 0.00
(-0.07%)

EQUITY - MARKET SCREENER

SJVN Ltd
Industry :  Power Generation And Supply
BSE Code
ISIN Demat
Book Value()
533206
INE002L01015
36.3431032
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SJVN
40.99
36888.99
EPS(TTM)
Face Value()
Div & Yield %
2.29
10
1.56
 

Sun Pharma drops as foreign broker downgrades on valuation, execution risks
Aug 26,2025
The broker cited stretched valuations and slower-than-expected traction in speciality drugs. It flagged concerns around psoriasis drug Ilumya's heavy Medicare exposure, potential pricing pressures, and limited earnings visibility despite strong initial uptake. It warned that a 10% price cut in Ilumya could erode Sun Pharma’s EPS by 4%.

Sun Pharmaceutical Industries is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets.

The company’s consolidated net profit tumbled 19.64% to Rs 2,278.63 crore despite of 10.07% increase in revenue from operations to Rs 13,786.07 crore in Q1 FY26 over Q1 FY25. The drop in profit was primarily due to a one-time exceptional charge of Rs 818 crore during the quarter.